{"nctId":"NCT01905956","briefTitle":"Safety and Efficacy of IQP- AK-102 in Reducing Body Weight","startDateStruct":{"date":"2013-07"},"conditions":["Weight Loss"],"count":119,"armGroups":[{"label":"IQP-AK-102","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: IQP-AK-102"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]}],"interventions":[{"name":"IQP-AK-102","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 to 65 years\n* 25≤BMI≤35\n* Expressed desire for weight loss\n* Accustomed to 3 main meals/day\n* Generally in good health\n* Consistent and stable body weight 3 months prior to study enrolment\n* Consistent regular physical activity\n* Commitment to avoid the use of other weight loss products during study\n* Commitment to adhere to diet and lifestyle recommended for the study\n\nExclusion Criteria:\n\n* Known sensitivity to the ingredients of the device\n* Presence of any active gastrointestinal disease\n* Malabsorption disorders\n* Pancreatitis\n* Stenosis in the GI tract\n* Bariatric surgery\n* Any other reason deemed suitable for exclusion, per investigator's judgement","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Body Weight From Baseline to Week 12","description":"Body weight (kg) was measured in subjects wearing underwear and no shoes using calibrated weighing scales (Tanita BC-420 SMA).\n\nResults were reported as value at baseline minus value at week-12, ie. amount of weight loss in (kg) (positive values).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.53","spread":"2.28"},{"groupId":"OG001","value":"0.14","spread":"1.84"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Waist and Hip Circumference (cm) From Baseline to Week 12","description":"Waist circumference (cm) was measured at the level midway between the lateral lower rib margin and the iliac crest.\n\nHip circumference (cm) was measured as the maximal circumference over the buttocks.\n\nResults were reported as value at baseline minus value at week-12, ie. amount of waist and hip circumference reduction (cm) (positive values).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":"2.99"},{"groupId":"OG001","value":"0.92","spread":"3.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":"2.41"},{"groupId":"OG001","value":"1.07","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Body Fat Content (%) From Baseline to Week 12","description":"Body fat content (%) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).\n\nResults were reported as value at baseline minus value at week-12, ie. reduction of body fat content (%) (positive values).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"2.91"},{"groupId":"OG001","value":"0.08","spread":"1.90"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Body Fat Mass (kg) From Baseline to Week 12","description":"Body fat mass kg) was measured by bio-impedance method using validated electronic weighing scales (Tanita BC-420 SMA).\n\nResults were reported as value at baseline minus value at week-12, ie. reduction of body fat mass kg) (positive values).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"2.91"},{"groupId":"OG001","value":"0.05","spread":"1.95"}]}]}]},{"type":"SECONDARY","title":"Food Craving Questionnaire (FCQ)","description":"This validated questionnaire evaluates changes in food cravings. It contains 15 items and was completed by the subjects based on the momentary feeling at the study site during visits 2 to 5 (Baseline and week 4, 8 and 12). Assessment was based on the following 5-point Likert scale:\n\n1. = I do not agree at all\n2. = I do not agree\n3. = Neutral\n4. = I agree\n5. = I highly agree\n\nResults were expressed as the mean score for the whole population in the respective intervention group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"1.28"},{"groupId":"OG001","value":"2.74","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"0.94"},{"groupId":"OG001","value":"2.47","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"0.96"},{"groupId":"OG001","value":"2.34","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","spread":"1.08"},{"groupId":"OG001","value":"2.47","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of Efficacy by the Investigators","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of Efficacy by the Subjects","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of Safety by the Investigators","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of Safety by the Subjects","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":58},"commonTop":["Common cold or upper respiratory tract infection","Headaches and Migraine","Toothache or dental extraction","Distortion and contusion of knee","Nausea & Vomiting"]}}}